Why reduce polypharmacy (multiple medication) burden?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025 • View editorial policy

From the Guidelines

Reducing pill burden is crucial to minimize the risk of falls, mortality, and other adverse outcomes, as evidenced by a study of 5213 participants in England, which found a 21% higher rate of falls in people taking 4 or more medications compared to those taking fewer 1. When considering the management of polypharmacy, it is essential to assess and interview the patient, reconcile medications, and systematically identify drug therapy problems, as highlighted in the study published in the Mayo Clinic Proceedings 1. Key points to consider when reducing pill burden include:

  • Simplifying the regimen for ambulatory patients and in long-term care to reduce hospitalizations or negative incidents 1
  • Avoiding drug therapy problems and risk of rehospitalizations by choosing pharmacotherapy carefully, such as tapering benzodiazepines, opioids, and others 1
  • Being aware of the increased risk of mortality as the number of medications rises, with a meta-analysis suggesting a progressive increase in risk from 1 to 4 medications (adjusted odds ratio [aOR] 1.24 [1.10 to 1.39]) up to aOR 1.96 [1.42 to 2.71] for those taking >9 medications 1 By reducing pill burden, patients can experience improved medication adherence, reduced risk of medication errors, and decreased side effects, ultimately leading to better health outcomes and improved quality of life.

From the Research

Reducing Pill Burden

Reducing pill burden is essential for improving medication adherence and health outcomes. The following points highlight the importance of reducing pill burden:

  • Fixed-dose combination therapy reduces pill burden and may improve medication adherence and health outcomes 2
  • A higher pill burden is directly and significantly associated with decreased adherence and persistence with antihypertensive therapies in real-practice settings 2
  • Reducing pill burden can lead to a significant improvement in adherence to pharmacological therapy of type 2 diabetes compared to a loose-dose combination 3
  • Fixed-dose combinations can simplify the treatment regimen by reducing pill burden compared with the same combination delivered as separate pills, leading to improved adherence 4

Benefits of Reducing Pill Burden

The benefits of reducing pill burden include:

  • Improved medication adherence 2, 3, 4
  • Increased persistence with treatment 2, 3
  • Better disease management, particularly among patients with complex medication demands or poor medication adherence 3
  • Potential for improved clinical outcomes 2, 3

Strategies for Reducing Pill Burden

Strategies for reducing pill burden include:

  • Fixed-dose combination therapy 2, 3, 4, 5
  • Once-daily dosing 5
  • Combination of fixed-dose and once-daily dosing 5
  • Use of single-pill, fixed-dose combinations, such as valsartan and amlodipine for hypertension 6

Related Questions

What is a suitable replacement for Lisinopril (Angiotensin-Converting Enzyme Inhibitor) in a patient with hyperkalemia, taking Amlodipine (Calcium Channel Blocker) and Coreg (Carvedilol, Beta Blocker)?
What are the advantages of fixed drug combination (FDC) except for cheaper cost, increased efficacy, better compliance, and reduced resistance?
Is Amlodipine (Amlor) related to any drug group and is Valsartan related to any drug group?
What are the ethical considerations when a patient experiences adverse effects from a medication, but wishes to continue treatment due to its therapeutic benefits?
What is the optimal management plan for a 70-year-old male with End-Stage Renal Disease (ESRD) on Hemodialysis (HD), resistant Hypertension (HTN), Heart Failure with preserved Ejection Fraction (HFpEF), Coronary Artery Disease (CAD), Gastroesophageal Reflux Disease (GERD), and Type 2 Diabetes Mellitus (T2DM), who presents with improved symptoms after hospital discharge for hypertensive urgency and hematemesis, and is currently taking carvedilol (Coreg) (carvedilol), lisinopril (Zestril) (lisinopril), amlodipine (Norvasc) (amlodipine), doxazosin (Cardura) (doxazosin), hydralazine (Apresoline) (hydralazine), and furosemide (Lasix) (furosemide)?
What are the treatment options for postnasal drip (PND) in the elderly?
What are the classifications and spectrum of activity of available antibiotics for educational purposes for Physician Assistant (PA) students?
What is the treatment for papular urticaria?
How often should patients with type 2 diabetes mellitus (T2DM) check their blood glucose levels using a point-of-care (POC) device?
What is the diagnostic workup for a 10-year-old patient with seizures and café au lait spots, suggestive of Neurofibromatosis type 1 (NF1)?
What is the LDL goal for a 50-year-old patient with Type 1 Diabetes Mellitus (T1DM) and no history of Atherosclerotic Cardiovascular Disease (ASCVD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.